The company said it expects to release additional data and regulatory strategy update from the Phase 2 GALLOP trial that is evaluating imsidolimabÂ in the second half of 2020.FDA Accepts AstraZeneca's Application For Brilinta Label Expansion With Priority Review AstraZeneca plc (NYSE: AZN) said the FDA has accepted a supplemental New Drug Application and granted Priority Review for Brilinta for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack.